<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weber, D.M.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Delasalle, K.</style></author><author><style face="normal" font="default" size="100%">Rankin, K.</style></author><author><style face="normal" font="default" size="100%">Gavino, M.</style></author><author><style face="normal" font="default" size="100%">Alexanian, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia</style></title><secondary-title><style face="normal" font="default" size="100%">Seminars in Oncology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2003</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037396195&amp;doi=10.1053%2fsonc.2003.50070&amp;partnerID=40&amp;md5=cbf89adc74ed9fd4850d2d96f49b4197</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">30</style></volume><pages><style face="normal" font="default" size="100%">243 - 247</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Treatment for Waldenstrom's macroglobulinemia (WM) has usually been reserved for symptomatic patients and has included alkylating agent-steroid combinations and, more recently, nucleoside analogues. We now describe our experience with 2-chlorodeoxyadenosine (2-CdA) alone and in combination at our center. We treated 90 consecutive, previously untreated patients with symptomatic WM using either 2-CdA alone or in combination with other agents including prednisone (pred), cyclophosphamide (Cy), and rituximab (Rit) as follows: January 1991 to December 1992 - 2-CdA 0.1 mg/kg by continuous infusion (CI) over 24 hours for days (16 patients); December 1992 to December 1995 - 2-CdA 0.1 mg/kg CI over 24 hours for 7 days plus pred 60 mg/m2 orally daily for 7 days (20 patients); July 1996 to March 1998 - 2-CdA 1.5 mg/m2 by subcutaneous injection (SC) every 8 hours for 7 days plus Cy 40 mg/m2 orally twice daily for 7 days (37 patients); August 1999 to December 2001 - 2-CdA 1.5 mg/m2 SC every 8 hours for 7 days plus Cy 40 mg/m2 orally twice daily for 7 days plus Rit 375 mg/m2 by intravenous infusion (IV) weekly for 4 weeks (17 patients). For nearly all patients, a second course was repeated after at least 6 weeks. Responding patients were monitored without further treatment until relapse. Overall response (complete [CR] + partial response [PR]) was 94% for 2-CdA alone, 60% for 2-CdA/pred, 84% for 2-CdA/Cy, and 94% for 2-CdA/Cy/Rit. Median overall survival is 73 months for 2-CdA, 41 months for 2-CdA/pred, and has not been reached for 2-CdA/Cy or 2-CdA/Cy/Rit. Cause-specific survival for 2-CdA/pred is 78 months and has not been reached for all other programs. The only poor prognostic factor for cause-specific survival was hemoglobin &amp;lt; 9 g/dL. 2-CdA regimens provide excellent response rates and improve cause-specific survival, with minimal treatment and little toxicity. These observations support the potential role of 2-CdA regimens as the treatment of choice for previously untreated WM. © 2003 Elsevier Inc. All rights reserved.</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><notes><style face="normal" font="default" size="100%">Cited By :88Export Date: 21 February 2017</style></notes></record></records></xml>